Henry Schein In (HSIC): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report

By
A A A

Summary:
Henry Schein's adjusted EPS of $1.35 in the second-quarter of 2014 increased 9.8% year over year and also beat the Zacks Consensus Estimate by 1.5%. Revenues rose 9.3% to $2.62 billion, edging past the Zacks Consensus Estimate by 1.8%. Animal Health continued to perform well while the core dental business picked up. The recent strategic acquisitions are expected to add value to the business. With the animal health market growing at a rapid pace and showcasing favorable trends, we are confident about further sales improvement. However, the overall macroeconomic uncertainty remains as overhang. Further, intense competition and currency fluctuations warrant caution. Moreover, as GPOs gain prominence, pricing pressure is inevitable. We still believe that the company's diversified distribution business offers resilience against macroeconomic volatility. Thus, we remain Neutral on the stock.

Overview:

Headquartered in Melville, NY, Henry Schein Inc. (HSIC) is a leading distributor of health care products and services across the globe. The company serves office-based dental, medical and animal health practitioners, dental laboratories, government as well as institutional health care clinics and other alternate-care sites. Presently, Henry Schein operates in 25 countries.

At the end of 2012, the company served a vast distribution network worldwide with a selection of over 96,000 branded products. Additionally, Henry Schein offers other value-added services such as practice management software, e-commerce solutions and an array of financial services.

Henry Schein's four businesses Dental, Animal Health, Medical and Technology and Value-Added Services serve millions of customers worldwide. In 2013, the company recorded global net revenue of $9.56 billion, with annualized growth of 6.9%.

Source: Company


Henry Schein In (HSIC): Read the Full Research Report
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

HENRY SCHEIN IN (HSIC): Free Stock Analysis Report

To read this article on Zacks.com click here.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Stocks

Referenced Stocks: HSIC

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

100%

Most Active by Volume

75,031,044
  • $16.26 ▲ 0.31%
64,683,841
  • $99.76 ▲ 2.14%
44,561,744
  • $14 ▼ 6.23%
37,984,130
  • $27.93 ▲ 0.36%
36,148,020
  • $94.39 ▲ 1.49%
33,981,456
  • $22.93 ▼ 1.38%
33,971,527
  • $44.08 ▲ 1.03%
33,685,322
  • $76.95 ▲ 1.32%
As of 10/20/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com